There are various respiratory conditions including bronchitis, allergies, and the common cold. But unfortunately, many of the current medications used for the relief of symptoms associated with cough, cold, and allergy are less than effective and this represents a significant unmet need.
A novel liquid formulation of an antitussive and other undisclosed active ingredients, CL-AT-313 will be investigated for the relief of cough and other symptoms associated with upper respiratory allergies and the common cold.
Pre-Clinical research takes place before any human testing is done using animals to find out if a drug, procedure, or treatment is likely to be useful.
Phase 1 clinical trials are classified as early stage studies for up to 1 month in duration on 20-80 healthy volunteers to evaluate the safety, appropriate dose range, toxicity limits, and side effects of a new drug or treatment.
Phase 2 clinical trials are classified as late stage studies on 200 to 300 individuals for up to several months’ duration on patients with a specific targeted disease to further evaluate the safety, effectiveness, and short-term side effects of the new drug.
Phase 3 clinical trials are classified as final stage studies on hundreds to thousands of patients that can last several years to confirm safety and effectiveness compared to commonly used products, monitor side effects and obtain further data on secondary endpoints that will help the new drug be used safely.
The NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.